Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Change in Receivables: 2012-2025

Historic Change in Receivables for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Sep 2025 value amounting to -$1.5 million.

  • Enanta Pharmaceuticals' Change in Receivables rose 5.16% to -$1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $236,000, marking a year-over-year increase of 111.99%. This contributed to the annual value of $236,000 for FY2025, which is 111.99% up from last year.
  • Enanta Pharmaceuticals' Change in Receivables amounted to -$1.5 million in Q3 2025, which was down 194.16% from $1.5 million recorded in Q2 2025.
  • Over the past 5 years, Enanta Pharmaceuticals' Change in Receivables peaked at $4.1 million during Q4 2021, and registered a low of -$11.6 million during Q1 2021.
  • Moreover, its 3-year median value for Change in Receivables was -$441,000 (2023), whereas its average is -$1.4 million.
  • Per our database at Business Quant, Enanta Pharmaceuticals' Change in Receivables slumped by 1,325.03% in 2023 and then surged by 343.08% in 2024.
  • Quarterly analysis of 5 years shows Enanta Pharmaceuticals' Change in Receivables stood at $4.1 million in 2021, then crashed by 44.33% to $2.3 million in 2022, then crashed by 119.45% to -$441,000 in 2023, then soared by 343.08% to $1.1 million in 2024, then rose by 5.16% to -$1.5 million in 2025.
  • Its Change in Receivables stands at -$1.5 million for Q3 2025, versus $1.5 million for Q2 2025 and -$926,000 for Q1 2025.